|Time Commitment:||3.5 hours over 6 weeks|
|Target Professions:||MD, Nurse, Nurse Practitioner, Physician Assistant, Pharmacist, DO|
|Target Specialties:||Family Medicine, Hematology, Internal Medicine, Oncology, Pharmacy|
|Credits Available:||3.5 AMA PRA Category 1 Credits™ for physicians; 3.5 ANCC Contact Hours for nurses and nurse practitioners, 3.5 ACPE Continuing Pharmacy Education Credits|
3.5-credit-hour educational curriculum that brings together 10 groups of 10 professionally connected clinicians led by an expert (called a Group Leader) to comprehensively review key information and best practices to help clinicians formulate their own practice action plans in the care of patients with DLBCL.
Answer the following questions to assess your knowledge on the management of refractory/relapsed DLBCL.
In self-study Module 1 you can review the effectiveness and safety data on using CAR T-cell therapies in patients with refractory and relapsed DLBCL by looking at a patient case discussion.
In self-study Module 2 you can review new and emerging treatment options for patients with previously treated DLBCL by looking at a patient case discussion.
Now that you have reviewed the self-study modules, answer the following questions to assess your gained knowledge on the assessment of and treatment options for refractory and relapsed DLBCL.
The purpose of this discussion is to review identified gaps in knowledge, competence, and confidence related to the care of patients with DLBCL, both through self-analysis and through review of the pre-assessment data.
The purpose of this discussion is to present the two case studies and provide an analysis of the responses. During this discussion, action plans will also be presented as we reflect on how our practice will change as a result of this CME activity.
Meet John Z, a 69 year old male presenting with a relapsed diffuse large B-cell lymphoma.
Meet AM, a 77-year-old white female with stage 4 diffuse large B-cell lymphoma (DLBCL), concerned with treatment options and challenges to receiving treatment.
In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with DLBCL.